Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD8 PET imaging in metastatic solid tumours
2024-515885-15-00Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 2
01
Overview
Phase 2, open-label trial of [89Zr]Zr-Df-Crefmirlimab in Nonhematologic neoplasms (2 arms), sponsored by University Medical Center Groningen. Planned start Nov 2024; status: authorised.
02
Drugs
[89Zr]Zr-Df-Crefmirlimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-515885-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515885-15-00.